Nature Medicine publishes the first human Akkermansia muciniphila trial

Researchers reported the first human trial of Akkermansia muciniphila, a gut bacterium studied for its ties to metabolic health, in the July 1, 2019 issue of Nature Medicine ^[2]. The randomized, double-blind, placebo-controlled pilot study enrolled 40 overweight or obese adults with insulin resistance, and 32 completed the three-month trial ^[2]. The main goals were to check safety, tolerability, and effects on metabolic markers such as insulin resistance, blood lipids, and body weight ^[2].

Participants took a daily oral dose of 10 billion bacteria, either live or pasteurized, for three months ^[2]. Compared with placebo, the pasteurized form of the bacterium improved insulin sensitivity by 28.62%, with a P value of 0.002, meaning the result was very unlikely due to chance ^[2]. Insulin levels in the blood dropped by 34.08% compared with placebo, and total cholesterol fell by 8.68% ^[2]. Both changes were statistically significant, according to the study authors ^[2].

Body weight told a different story. People taking pasteurized Akkermansia muciniphila lost 2.27 kilograms more than those on placebo, but the P value was 0.091, above the standard 0.05 cutoff scientists use to call a result statistically significant ^[2]. In plain terms, the weight loss trend looked real but was not strong enough, by usual scientific standards, to rule out chance. The same pattern held for fat mass, which fell by 1.37 kilograms compared with baseline, and hip circumference, which dropped by 2.63 centimeters compared with baseline, both with P values of 0.091 to 0.092 ^[2]. Researchers also found that daily supplementation, in either live or pasteurized form, was safe and well tolerated across the study period ^[2].

Why it matters for patients

This was a small, early-stage trial, not a large study of a marketed product. It included only 32 people who finished the study, which limits how confidently the findings can be applied to a broader population ^[2]. The study was designed mainly to test safety and to look for signals worth studying further, not to prove the bacterium causes meaningful weight loss ^[2].

For people already using or considering GLP-1 medications such as semaglutide (Ozempic, Wegovy, Rybelsus) or tirzepatide (Mounjaro, Zepbound), this research does not change how those drugs work or what they do. It points to a different, much earlier line of research into the gut microbiome and metabolic health. The insulin sensitivity and cholesterol results are notable because they reached statistical significance in this small group, but the body weight results did not, which is an important distinction the study authors themselves highlighted ^[2].

Anyone reading about this trial should keep in mind that a single early-phase study, even one published in a major journal, is not the same as a treatment ready for pharmacy shelves. Larger and longer trials would be needed to confirm these results and to establish real-world effectiveness and safety.

What happens next

The sources provided do not describe any follow-up trials, regulatory filings, or commercial products tied to this specific study. It is not yet known from the available sources whether larger human trials of Akkermansia muciniphila have since been planned or completed, or whether the pasteurized bacterium has advanced toward any approved use.